

Zhi Wang^{1,2}, Laura E. Pascal², Uma R. Chandran³, Srilakshmi Chaparala³, Shidong Lv^{2,4}, Hui Ding², Lin Qi¹, Zhou Wang^{2,5,6,7} ¹Department of Urology, Xiangya Hospital of Central South University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University of Pittsburgh, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, PA; ⁴Department of Urology, Nanfang Hospital, Southern Medical Informatics, University, Southern Medical Informatics, University, Southern Medical Informatics, University, Southern Medical Informatics, University, Southern Medical Informati University, Guangzhou, Guangdong, China; ⁵UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁷Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁷Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁷Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh School of Medicine, Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁸Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh School of Pittsburgh School of Pittsburgh School of Pittsburgh School of Medicine, Pittsburgh School of Pittsb School of Medicine, Pittsburgh, PA, USA

Background: Elongation Factor for RNA Polymerase II, 2 (ELL2) was reported as a putative tumor suppressor in the prostate. ELL2 is frequently downregulated in prostatic adenocarcinoma specimens, and loss of ELL2 induced murine prostatic intraepithelial neoplasia and enhanced AR-positive prostate cancer cell proliferation. However, ELL2 gene appears to be amplified in ARnegative neuroendocrine prostate tumors, suggesting a potential oncogenic role for ELL2 in AR-negative prostate cancer cells. In this study, we explored potential function of ELL2 in PC-3 and DU145, two AR-negative prostate cancer cell lines.

Methods: The role of ELL2 in PC-3 and DU145 cells was studied using siRNAmediated ELL2 knockdown. Genes regulated by ELL2 knockdown in PC-3 cells were identified and analyzed using RNA-Seq and bioinformatics. Expression of representative genes was confirmed by Western blot and/or quantitative PCR. Cell growth was determined by BrdU, MTT and colony formation assays. Cell death was analyzed by 7-AAD/Annexin V staining and trypan blue exclusion staining. Cell cycle was determined by PI staining and flow cytometry.

Results: ELL2 knockdown inhibited proliferation of PC-3 and DU145 cells. RNA-Seq analysis showed an enrichment in genes associated with cell death and survival following ELL2 knockdown. The interferon-y pathway was identified as the top canonical pathway comprising of 55.6% of the genes regulated by ELL2. ELL2 knockdown induced an increase in STAT1 and IRF1 mRNA and an induction of total STAT1 and phosphorylated STAT1 protein. Inhibition of cell proliferation by ELL2 knockdown was partly abrogated by STAT1 knockdown. ELL2 knockdown inhibited colony formation and induced apoptosis in both PC-3 and DU145 cells. Furthermore, knockdown of ELL2 caused S-phase cell cycle arrest, inhibition of CDK2 phosphorylation and cyclin D1 expression, and increased expression of cyclin E. Conclusions: ELL2 knockdown in PC-3 and DU145 cells induced S-phase cell cycle arrest and profound apoptosis, which was accompanied by the induction

of genes associated with cell death and survival pathways. These observations suggest that ELL2 is a potential oncogenic protein required for survival and proliferation in AR-negative prostate cancer cells.



Cyclin D

Fig.4 Effect of ELL2 and STAT1 knockdown individually or in combination (siDouble) on colony formation. PC-3 (A) and DU145 (B) cells were treated with indicated siRNAs as descdribed in Fig. 5, prior to colony formation assay. The colonies were visualized by crystal violet staining. The colonies in each dish were imaged by ChemiDoc[™] Touch Imaging System and counted by Image Pro Plus software for each group of cells. *, p < 0.05, *** p < 0.001, **** p < 0.0001.

Putative tumor suppressor ELL2 is required for proliferation and survival of AR-negative prostate cancer cells

Cell Proliferation In ELL2-knockdown AR-negative Cells



Fig. 1 Impact of ELL2 knockdown on BrdU incorporation in AR-negative prostate cancer cells. Images shown are BrdU-positive nuclei in PC-3 cells (A) or DU145 (B) transfected with 25 nM nontarget control siRNA (siControl) or two different siRNAs targeting ELL2 (#1 or #2). DAPI staining shows all the nuclei. BrdU incorporation was quantified by determining the mean percentage ± SD of BrdUpositive cells relative to the total number of cells. Cells were counted from two different fields for each well from triplicate wells and 30-130 cells per field C.Efficiency of siELL2 knockdown in PC-3 cells was verified by western blotting. ELL2 band denoted by black arrow. GAPDH was used as a loading control. Results are representative of three individual experiments. ** p < 0.01, *** p < 0.001.



siELL2+25 nM siControl), target to STAT1 (25 nM siSTAT1+25 nM siControl) and both (25 nM siELL2+25 nM siSTAT1) (siDouble). Upper panel shows BrdUpositive nuclei (red), and lower panel shows nuclear staining with DAPI (Blue). Images were acquired using an 40x objective. Quantification of BrdU incorporation is shown as mean percentage ± SD of BrdU-positive cells relative to the total number of cells. Cells were counted from two different fields for each well from triplicate wells and 50-170 cells per field. * p < 0.05; ** p < 0.01, *** p < 0.010.001.



Fig 6. PC-3 cells (A) were treated with 25nM siELL2 or combination of siELL2 and siSTAT1, while DU145 cells (B) were transfected with 25nM siELL2, with 1.3 to 3-fold increase of cell populations of ELL2-knockdown group in S phase compared to control group, as assessed by flow cytometry. *p<0.05, ** p< 0.01, *** p < 0.001, ****p<0.0001). C. PC-3 and DU145 cells were untreated or were transfected siELL2, siSTAT1or both for 72 h and analyzed for the expressions of cyclin D,p-CDK2, and cycllin E by Western blotting. GAPDH was used as a loading control. ELL2 knockdown induces cyclin Eexpression and repressed cell cycle related p-CDK2 and

Fig. 7. A. Trypan blue exclusion assay of cell death of PC-3 and DU145 cells transfected with indicated siRNA as described in Fig. 5. Data represent the means ± SD. Cell apoptosis was analyzed with Flow cytometry apoptosis analysis using Annexin V-FITC/7-AAD in PC-3 (B) and DU145 (C) cells transfected with indicated siRNAs. D. PC-3 and DU145 cells were untreated or were transfected siELL2, siSTAT1 or both for 72 h and analyzed for knockdown efficiency. ELL2 band denoted by black arrow. GAPDH was used as a loading control. ** p< 0.01, *** p < 0.001, **** p < 0.0001.